Biological Signal Processing Ltd Integrates Flagship Product, HyperQ™ Stress System, into Leading U.S. Hospitals & Academic Centers
Published: Jul 15, 2008
BSP (Biological Signal Processing Ltd.), a ground-breaking Israeli company that develops and markets innovative systems for the non-invasive diagnosis and monitoring of ischemic heart disease (IHD), announced the incorporation of their HyperQ™ Stress System into leading hospitals and academic centers for cardiac care across the U.S.
The HyperQ™ Stress System is cutting-edge technology implemented in an innovative stress test system, offering highly reliable, accurate and cost effective testing for IHD patients. The system is based on proprietary signal analysis of the high frequency components of the QRS complex in the ECG.
"We have received enthusiastic responses upon launching the HyperQ™ System in the U.S.. The first system is currently operating at the Washington Hospital Center in Washington, D.C.. Additional systems will be installed into other leading centers in West Virginia, San Diego and Los Angeles," said Dr. Amir Beker, CEO of BSP.
"The HyperQ system will be utilized in a carefully planned research protocol here at Washington Hospital Center. The protocol is designed to validate the clinical value of HyperQ in the diagnosis of ischemic heart disease" said Dr. Jared M. Widell, Director of the Stress Echocardiography Laboratory at Washington Hospital Center.
Pilot studies will be designed to test the accuracy of the HyperQ™ system in the general US population for cardiac patients and in certain subgroups such as women, African-American, and diabetic patients.
Dr. Beker adds, "Under the guidance of BSP's Scientific Advisory Board, these and other sites will become part of a large multi-center study planned for later this year. In this focused effort, the HyperQ™ system will be tested and used as part of the validation process in the US. It is anticipated that this will lead to the implementation of the HyperQ™ technology as an integral part of care in cardiac patients."
BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of ischemic heart disease. More than 5000 patients in Israel, Europe and the U.S. have been examined by the HyperQ™ Stress System in controlled clinical studies, pilot programs and routine operation. The system has received FDA clearance (510K) and CE marking.
BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau. BSP completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange. The company's international offices are located in Tel Aviv, Israel and the U.S. offices are in Rockville, Maryland.
Dr. Amir Beker, CEO
Dr. Neri Malka, Head of Clinical Marketing
Tel: +972 3 647 4840
Yamit Nissanov, IDAN Communications (PR)
+972-9-9514666, +972-52-5541810 or email@example.com